skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In Honor of Psoriasis Awareness Month

Prevalent cases of psoriasis are anticipated to grow by 5.2% over the next decade in the US, Japan, and five major EU markets. To get a quick world view of the current psoriasis and psoriatic arthritis (PsA) landscape, download your COMPLIMENTARY infographic.

Get a clear perspective of the following:

  • Psoriasis severity prevalence proportions and total cases in 2016, by country (US, Germany, Italy, France, Spain, UK, Japan)
  • Psoriasis and PsA drugs in recently completed, ongoing, and planned registration studies (includes trials completed within the last two years)
  • Number of deals for psoriasis and psoriatic arthritis and average deal value
  • Partnered products
  • Psoriasis and PsA licensing deals by company types and role
  • The biosimilar landscape
  • Upcoming regulatory catalysts for biosimilars, including likelihood of approval (LOA) relative to average
  • Patients switched to etanercept biosimilar, by country